RT Journal Article SR Electronic T1 Assessment of impact of the COVID-19 pandemic from the perspective of patients with rheumatic and musculoskeletal diseases in Europe: results from the REUMAVID study (phase 1) JF RMD Open JO RMD Open FD EULAR SP e001546 DO 10.1136/rmdopen-2020-001546 VO 7 IS 1 A1 Marco Garrido-Cumbrera A1 Helena Marzo-Ortega A1 Laura Christen A1 Pedro Plazuelo-Ramos A1 Dale Webb A1 Clare Jacklin A1 Shantel Irwin A1 Laurent Grange A1 Souzi Makri A1 Elsa Frazão Mateus A1 Serena Mingolla A1 Katy Antonopoulou A1 Sergio Sanz-Gómez A1 José Correa-Fernández A1 Loreto Carmona A1 Victoria Navarro-Compán YR 2021 UL http://rmdopen.bmj.com/content/7/1/e001546.abstract AB Aim To assess the impact of the COVID-19 pandemic on patients with rheumatic and musculoskeletal diseases (RMDs).Methods REUMAVID is a cross-sectional study using an online survey developed by an international multidisciplinary patient-led collaboration across seven European countries targeting unselected patients with RMDs. Healthcare access, daily activities, disease activity and function, well-being (WHO Five Well-Being Index (WHO-5)), health status, anxiety/depression (Hospital Anxiety and Depression Scale (HADS)) and access to information were evaluated. Data were collected in April–July 2020 (first phase).Results Data from the first phase included 1800 patients with 15 different RMDs (37.2% axial spondyloarthritis, 29.2% rheumatoid arthritis, 17.2% osteoarthritis and others). Mean age was 53, 80% female and 49% had undertaken university studies. During the beginning of the pandemic, 58.4% had their rheumatology appointment cancelled and 45.6% reported not having received any information relating to the possible impact of SARS-CoV-2 infection in their RMDs, with the main source being patient organisations (27.6%).Regarding habits, 24.6% increased smoking, 18.2% raised their alcohol consumption, and 45.6% were unable to continue exercising. Self-reported disease activity was high (5.3±2.7) and 75.6% reported elevated pain. Half the patients (49.0%) reported poor well-being (WHO-5) and 46.6% that their health had changed for the worse during lockdown. According to HADS, 57.3% were at risk of anxiety and 45.9% of depression.Conclusion Throughout the first wave of the COVID-19 pandemic, patients with RMDs have experienced disruption in access to healthcare services, poor lifestyle habits and negative effects on their overall health, well-being and mental health. Furthermore, information on COVID-19 has not reached patients appropriately.Deidentified participant data are available on reasonable request to MG-C.